Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma	Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, follicular lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm	Recruiting	Phase 2	2026-03-23		NCT04998669

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
ADC Therapeutics S.A.	12
Juan P. Alderuccio, MD	2

5 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Allegheny Health Network	Pittsburgh	United States	35
Florida Cancer Specialists and Research Institute	Fort Myers	United States	1
Rutgers Cancer Institute of New Jersey	New Brunswick	United States	67
University of Miami	Miami	United States	327
University of Michigan	Ann Arbor	United States	538